Pipeline
The core production technique and manufacture
The molecular weight of OBI-858 is a 760 kDa novel toxin protein which fermented and purified from Clostridium botulinum type A bacteria. From the very beginning, OBIGEN selects the unique Taiwan strains that can compete with commercially available products. Production has reached commercial-scale yields and product quality meets pharmaceutical standards. It also contains trehalose as an excipient, providing a different type of botulinum toxin from the existing ones in the market. OBIGEN has built an API plant that meets the standards of the International Organization for the Inspection of Pharmaceutical Products (PIC/s GMP) in the Zhubei Biomedical Science Park, and the dedicated production facility of finished dosage forms for clinical and commercialization purposes.
Patented Strain
OBIGEN selects the unique Taiwan strains that can compete with commercially available products. Originated from the same bacterial species as those on the market. Such bacteria are regulated as biological warfare internationally.
Manufacture Site
OBIGEN has built an API plant that meets the standards of the International Organization for the Inspection of Pharmaceutical Products (PIC/s GMP) and the dedicated production facility of finished dosage forms for clinical and commercialization purposes.
Product development
Abide by the highest quality requirement and safety standards, OBIGEN develops and manufactures the best quality botulinum toxin product and ensure the safety and stability result to provide consumers with a better choice for the pursuit of true beauty and quality of life.
